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Schedule of taking calcium supplement and the risk of
nephrolithiasis.
Background. Variation in the timing of calcium supplement
may affect gastrointestinal absorption of both calcium and ox-
alate differently and may associate with variable risk of calcium
oxalate nephrolithiasis. There are few human studies address-
ing specifically the appropriate time for taking calcium supple-
ment. Therefore, this study was performed to compare calcium
bioavailability and the risk of calcium oxalate stone formation
for calcium supplement taken with meal vs. taken at bedtime.
Methods. Thirty-two healthy male navy privates, 22.7 ± 1.9
years old (mean ± SD), who had normal renal function (serum
creatinine less than 150 umol/L) and no history of renal stone,
participated in the study. The subjects were randomly allocated
into two groups of 16 each. Group A took 1 g of calcium carbon-
ate with meal, 3 times/day; and group B took 3 g/day of calcium
carbonate at bedtime. After taking the regimens for 1 week, fol-
lowed by 1 month of washout period, crossover between both
groups was done. The diet was controlled throughout the study.
Twenty-four–hour urine collections for the determination of
urinary constituents were obtained at baseline and after tak-
ing both regimens of calcium supplement. Activity product for
calcium oxalate was determined to assess the risk of calcium
oxalate stone formation.
Results. Urinary excretions of calcium were significantly el-
evated above the baseline values when taking calcium supple-
ment both with meal (3.48 ± 2.13 mmol/day vs. 5.17 ± 2.61
mmol/day, P < 0.05) and at bedtime (3.09 ± 1.70 mmol/day vs.
5.08 ± 2.34 mmol/day, P < 0.05). There was no difference be-
tween the two regimens in the urinary calcium excretions. The
urinary oxalate was decreased significantly when the subjects
took calcium supplement with meal compared with the corre-
sponding baseline value (0.13 ± 0.05 vs. 0.17 ± 0.07 mmol/d,
P = 0.01). In contrast, there was no alteration in urinary ox-
alate when calcium supplement was taken at bedtime compared
to the baseline values (0.15 ± 0.05 mmol/day vs. 0.15 ± 0.06
mmol/day, P = 0.9). Compared with the corresponding baseline
values, there was no significant increase in the activity product
for calcium oxalate when taking calcium with meal (0.54 ± 0.25
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vs. 0.57 ± 0.22, P = 0.54), but it was increased significantly when
calcium supplement was taken at bedtime (0.47 ± 0.21 vs. 0.72
± 0.27, P < 0.01).
Conclusion. Calcium supplement should be taken with
meal in order to avoid increasing the risk of calcium oxalate
nephrolithiasis.
Because the combination of calcium and oxalate in
the intestine limits oxalate absorption, increased dietary
calcium intake has been shown to reduce urinary ox-
alate excretion in both healthy subjects and patients
with nephrolithiasis [1–5]. However, a prospective co-
hort study demonstrated that high dietary calcium intake
appeared to decrease risk while calcium supplement in-
creased the risk of urinary tract stones [6]. This paradox
was explained by the timing of taking calcium and the di-
etary oxalate content. Subjects who did not take calcium
supplement with their meal or whose dietary oxalate con-
tent was low had a higher risk of calcium stone formation
[6]. Although the explanation is sensible, it has never been
proven. Most studies which demonstrated the effect of
calcium intake on intestinal absorption of oxalate were
done under oxalate load, with the amount of oxalate be-
ing much higher than the oxalate content in a normal diet
[2, 5]. In addition, the effect of a different schedule of cal-
cium consumption on urinary constituents or on the risk
of stone formation was not taken into account.
It is still uncertain whether the combination of calcium
with oxalate in the intestine is the only mechanism for
decreasing the risk of calcium stone formation. A recent
animal study demonstrated that calcium oxalate could
be absorbed intact, without being dissociated prior to ab-
sorption [7]. Supplementation of calcium also provides
alkaline supplement from the anionic component of cal-
cium salt to the body. This may lead to an increase in cit-
rate excretion and thereby reduction in the risk of stone
formation [8]. Moreover, if dietary oxalate content is also
a major determinant of the effect of calcium supplement
on the risk of stone formation as postulated in the previ-
ous study [6], dietary oxalate content and/or the amount
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of urinary oxalate should be known before prescribing
calcium. We therefore conducted this study to determine
the effect of calcium supplement schedule on the risk of
calcium stone formation under normal diet.
METHODS
Subjects
Subjects were enrolled from healthy male navy privates
who worked as patient assistants in Arpakornkieatiwong
Hospital, the navy hospital in Sattahip Navy Base, Chon-
buri, Thailand. Inclusion criteria were (1) normal renal
function (serum creatinine <150 umol/L), (2) no history
of renal stone formation, and (3) no gastrointestinal dis-
eases or malabsorption syndrome. During the study, sub-
jects with the following conditions were excluded from
the study: (1) illness that needed hospitalization or ab-
sence from work, (2) acute diarrhea or a disease that af-
fected appetite or gastrointestinal absorption of food, and
(3) failure to follow the protocol strictly. There were 50
navy privates eligible for this study. However, only 38 of
them participated. Six subjects were excluded after en-
rollment due to the failure to comply with controlled diet
or inability to follow study protocol due to military duty
during the first week of study. Therefore, only 32 subjects
participated through out this study, their mean ± SD for
age, body weight, and height was 22.7 ± 1.9 years, 61.2 ±
7.4 kg, 169.3 ± 3.4 cm, respectively.
Study protocol
All subjects (N = 32) were on a controlled diet pro-
vided by the hospital cafeteria and stayed in the hospital
dormitory throughout the study. In phase 1, all subjects
were required to take only a controlled diet provided by
the investigator for 1 week. At day 6 and day 7 of the first
week of taking the controlled diet, the first baseline two
24-hour urine collections (U1) were obtained from each
subject. In the second week, the subjects were randomly
allocated into two groups. Group A (N = 16) took one
capsule of 650 mg of calcium carbonate immediately af-
ter meal, three times a day. Group B (N = 16) took three
capsules of 650 mg of calcium carbonate, at bedtime. Both
groups took the calcium supplements as well as the same
controlled diet for 1 week and an additional two 24-hour
urine collections (U2) were obtained from each subject
at day 6 and day 7 of the second week. Thereafter, each
subject went through a washout period of 4 weeks. Dur-
ing the washout period, each subject was allowed to have
his own choice of diet. After the washout period, both
groups went into phase 2 during which each subject was
on the same controlled diet as in phase 1. At the end
of 1 week with controlled diet, the second baseline two
24-hour urine collections (U3) were obtained from each
subject. Then, both groups were crossed over, group A
switched to take three capsules of 650 mg of calcium car-
bonate at bedtime while group B took one capsule of 650
mg of calcium carbonate with meal, three times a day
for 1 week. Two 24-hour urine collections (U4) were ob-
tained from each subject again on day 6 and day 7 of that
week. The diagram for the study protocol is shown in
Figure 1. All subjects had to take the calcium supple-
ments, both in phase 1 and in phase 2, under the supervi-
sion of a research nurse to ensure the compliance.
The controlled diet was the usual Thai diet with the
following major food compositions: total calories 2000 to
2500 kcal/day, carbohydrate 350 g/day, protein 80 g/day,
fat 60 g/day, calcium 10 to 15 mmol/day, and oxalate 0.6
to 1.2 mmol/day. The menu was set in cycle so that dur-
ing the corresponding days of the study, both in phase 1
and in phase 2, all subjects would have the same menu of
Domrongkitchaiporn et al: Calcium supplement and nephrolithiasis 1837
Table 1. Dietary record of major food compositions for the subjects
when calcium supplement was taken with meal or at bedtime
Calcium supplementa
Food compositions With meal At bedtime P value
Protein g/day 88.01 ± 10.75 85.4 ± 8.79 NS
Carbohydrate g/day 316.9 ± 57.08 332.3 ± 53.42 NS
Fat g/day 61.3 ± 9.09 62.9 ± 7.67 NS
Calciumb mmol/day 14.75 ± 1.81 14.55 ± 1.60 NS
Oxalate mmol/day 0.9 ± 0.06 0.9 ± 0.07 NS
Total calories kcal/day 2172.6 ± 270.3 2197.5 ± 258.0 NS
NS is not significant.
aThe numbers were calculated from the combination of group A and group B
when had the same calcium regimen.
bAmount of calcium intake contributed by the calcium supplement was not
included in the dietary record.
food. Each subject had his food intake exclusively at the
hospital cafeteria. A dietitian at the cafeteria recorded
the actual amount of the food taken by an individual
subject after he had finished each meal. The major food
compositions were determined by a nutritionist in accor-
dance with Thai food composition tables [9]. No vitamin
or any dietary supplement apart from what was provided
according to the study protocol was allowed during the
study.
Specimen collections and laboratory investigations
Urine samples were collected in plastic containers, us-
ing 10 g of boric acid as preservative. Urine volume and
urine constituents, including sodium, potassium, calcium,
magnesium, citrate, oxalate, phosphate, and creatinine
were determined immediately after each 24-hour collec-
tion. Creatinine, sodium, potassium, chloride, calcium,
and phosphate were determined by autoanalyzer tech-
nique, magnesium by atomic absorption spectrometry,
citrate by citrate lyase technique [10], and oxalate by high-
performance liquid chromatography (HPLC) technique
[11]. For the oxalate assay, the interassay coefficients of
variation averaged 4%, while the recovery of oxalate av-
eraged 93%. The amount of each urinary constituent used
for further analysis was derived from the average of the
two 24-hour urine collections. Risk of calcium oxalate
stone formation was determined by using the index of
Tiselius [12], where the ion activity product was estimated
by an index called AP (CaOx):
AP(CaOx)index = A× Ca0.84 × Ox1.0
× Mg−0.12 × Cit−0.22 × V−1.03
Urinary excretions of calcium (Ca), oxalate (Ox), magne-
sium (Mg), and citrate (Cit) were expressed in millimoles
per collection period, and urine volume (V) in liters.
Factor A was 1.9, depending on the collection time of
24 hours [12]. Calcium oxalate activity product value cal-
culated by the AP (CaOx) index was highly and positively
correlated (r = 0.98) with those obtained by the Equil
2 program [13]. The correlation between the index and
stone forming activity in calcium oxalate stone formers
has been demonstrated [14–16]. It is clinically useful and
has been recommended for a routine program of evalua-
tion and follow-up of stone-forming patients [17].
The study protocol was reviewed and approved by the
Office of Sattahip Navy Base Commander, Royal Thai
Navy, Thailand. A written informed consent was obtained
from each subject.
Statistical analysis
Data are presented as mean ± SD. Calculation of sam-
ple size based on the mean and standard deviation of
AP(CaOx), 0.33 ± 0.17, derived from 26 normal males
(aged 32.6 ± 10.8 years, weight 62.2 ± 12.3 kg). The alpha
error and statistical power was defined as 0.05 and 0.80,
respectively. Clinical relevance of the difference between
the mean of AP(CaOx) was defined as = 0.17. Therefore,
the estimated sample size was 12 persons in each group
for repeated measurement [18].
Paired or unpaired t tests were applied to determine the
differences of group means for dependent or independent
samples, respectively. A P value of less than 0.05 was
considered statistically significant.
RESULTS
The dietary records demonstrated that each of the 32
subjects had dietary intake according to the protocol.
There was no significant difference in the major food
compositions when calcium supplement was taken with
meal or at bedtime, as shown in Table 1. The urine con-
stituents at baseline and when the subjects took either
regimen of calcium supplement are shown in Table 2.
There was no difference between either regimen in any
baseline urinary constituents. Urinary calcium increased
significantly with both regimens of calcium supplement
(Fig. 2A). There was no difference between the two reg-
imens in the urinary calcium excretions after taking cal-
cium supplement. The urinary oxalate was significantly
decreased (Fig. 2B), whereas the urinary citrate was el-
evated significantly above the baseline value only after
taking calcium supplement with meal (Fig. 2C). The uri-
nary citrate was also significantly higher after taking cal-
cium supplement with meal than after taking at bedtime
(P < 0.05). The AP(CaOx) was significantly elevated
above the corresponding baseline value only after tak-
ing calcium supplement at bedtime (P < 0.05) and was
also higher than the AP(CaOx) after taking calcium sup-
plement with meal (P < 0.05) (Table 2). There was no
significant alteration in AP(CaOx) from the correspond-
ing baseline value after taking calcium supplement with
meal. Urinary excretion of calcium, citrate, and oxalate
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Table 2. Urinary constituents and AP(CaOx) at baseline and during calcium supplement with meal or at bedtime
Calcium supplement with meal Calcium supplement at bedtime
Urine constituents mmol/day Baseline Calcium supplement Baseline Calcium supplement
Creatinine 16.85 ± 6.15 14.50 ± 8.69 15.82 ± 6.36 14.08 ± 6.16
Urea 223.06 ± 58.22 254.04 ± 108.20 218.74 ± 48.11 231.99 ± 68.85
Uric acid 3.06 ± 0.97 2.84 ± 1.80 3.19 ± 0.81 2.86 ± 1.26
Calcium 3.48 ± 2.13 5.17 ± 2.61a 3.09 ± 1.70 5.08 ± 2.34a
Phosphate 19.64 ± 8.08 19.49 ± 8.74 20.79 ± 6.84 19.97 ± 5.54
Sodium 147.3 ± 67.5 166.2 ± 65.08 146.7 ± 45.8 168.1 ± 47.28
Potassium 21.0 ± 7.1 26.6 ± 13.28 21.9 ± 8.0 24.8 ± 9.65
Chloride 178.4 ± 73.0 201.3 ± 73.3 179.6 ± 49.9 201.4 ± 51.6
Magnesium 3.60 ± 1.20 3.80 ± 1.20 3.51 ± 1.40 3.80 ± 1.53
Oxalate 0.17 ± 0.07 0.13 ± 0.05a 0.15 ± 0.06 0.15 ± 0.05
Citrate 0.64 ± 0.39 0.83 ± 0.57a 0.68 ± 0.48 0.77 ± 0.62b
Volume L/day 1.66 ± 1.07 1.57 ± 0.78a 1.47 ± 0.49 1.49 ± 0.41
AP(CaOx) 0.54 ± 0.25 0.57 ± 0.22 0.47 ± 0.21 0.72 ± 0.27a,b
aP < 0.05 compared with corresponding baseline value; bP < 0.05 compared with calcium supplement with meal.
for individual subjects while they were on the two regi-
mens of calcium supplement are shown in Figure 2 and
the AP(CaOX) in Figure 3.
DISCUSSION
In this study we applied the index of Tiselius [12],
where the ion AP(CaOx) was estimated, to be a surrogate
marker for the risk of calcium oxalate stone formation.
The study demonstrated that there was no significant
alteration in the activity product for calcium oxalate
stone formation when calcium supplement was taken
with meal. Taking calcium supplement with meal resulted
in a lower urinary excretion of oxalate. The concomitant
elevation in urinary citrate and the reduction in urinary
oxalate counterbalanced the effect of elevation in uri-
nary calcium. In contrast, taking calcium supplement at
bedtime resulted in an elevation in calcium oxalate activ-
ity product. This resulted from the elevation in urinary
calcium without compensatory reduction in the urinary
oxalate and less elevation in the urinary citrate. For stone
formers or subjects whose AP(CaOx) had already been
high, the elevation in AP(CaOx) when calcium supple-
ment is taken at bedtime may be even higher. Based on
our findings, we recommend that calcium should be sup-
plemented with meal in order to avoid an increased risk
of calcium stone formation.
Although the study was performed under controlled
diet, the dietary contents and the kinds of food provided
by the dietitian were usual Thai diet, which were nor-
mally taken by the subjects. In fact, the oxalate intake in
our subjects was rather low compared to what have been
reported from other studies done in western populations
[17, 19, 20]. This was confirmed by the low urinary excre-
tion of oxalate at baseline. The amount of urinary oxalate,
as well as other urine constituents, found in our study
was in the range of what was reported in another study in
Thai population [21]. There was no oxalate loading in our
study. Our findings, therefore, argue against the postula-
tion that calcium supplement in subjects with low oxalate
intake might increase the risk of calcium stone formation
[6]. The findings from our study were consistent with the
findings from Hess et al [5], where the dosage of oxalate
intake was supraphysiologic. Based on the findings in our
study and the study of Hess et al [5], the effect of calcium
supplement with meal could be possibly even greater in a
population with a higher oxalate intake. However, further
study may be necessary to find out whether our findings
can be applied to populations where the dietary oxalate
intakes are higher.
There was no difference in the gastrointestinal calcium
absorption of the two calcium supplement regimens as
indicated by the comparable amount of urinary calcium
in both phases. Therefore, there is no advantage in taking
calcium at bedtime with respect to the amount of intesti-
nal calcium absorption. Our finding was in contrast to
a previous suggestion that recommended otherwise [22].
Although some suggested that calcium should be taken at
bedtime to reduce the nocturnal increase in bone remod-
eling, no available data indicate a greater beneficial effect
[22]. It should be pointed out that the dietary calcium in
our subjects was rather low compared to the amount in a
western diet. It is uncertain whether the beneficial effect
of taking calcium with meal would be the same or less in a
population with higher dietary calcium. Although the uri-
nary excretions of calcium were comparable for both reg-
imens of calcium supplement, our finding did not exclude
the possibility that taking calcium supplement at bedtime
or on an empty stomach could induce an acute elevation
in urinary calcium excretion and lead to an elevation in
AP(CaOx), especially a few hours after ingestion. This
could be another possible mechanism for an increase in
the urinary saturation for calcium oxalate. Since the ma-
jor cause of the reduction in AP(CaOx) was the decrease
in urinary oxalate, the timing of calcium supplement may
also vary by the oxalate content of the meal.
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Fig. 2. Urinary excretion of calcium (A), ox-
alate (B), and citrate (C) for individual pa-
tient when calcium supplement was taken with
meal and at bedtime. The cross line and er-
ror bar represents mean ± SD for the entire
group.
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Calcium supplements also increased urinary excretion
of citrate. This resulted from the intestinal absorption of
carbonate, the anion that accompanied the calcium salt.
The carbonate provided alkaline supplement to the body
leading to an elevation in urinary citrate excretion [8].
In our study, taking calcium either with meal or at bed-
time increased urinary citrate excretion over the baseline
value. However, citrate excretion was significantly higher
when calcium was taken with meal than when it was taken
at bedtime. Ingesting potassium citrate either with meal
or when given on an empty stomach appears to have no ef-
fect on urinary citrate excretion [23]. No study specifically
determined the effect of meal on urinary citrate excre-
tion when taking calcium carbonate supplement. There
is no clear explanation for the difference in urinary citrate
found in our study. We postulate that a higher proportion
of calcium may combine with oxalate resulting in higher
carbonate availability for intestinal absorption when it
was taken with meal. It should also be pointed out that uri-
nary citrate in our subjects was relatively low compared
to the levels reported in studies from western countries
[24]. The urinary excretion of citrate in Thai population,
either normal subjects or stone formers, is relatively low
[25, 26]. The levels found among our subjects were in the
ranges of other studies in Thai population [25, 26].
There were limitations in our study. First, it should be
noted that our subjects had no history of stone forma-
tion. Calcium handling may differ between subjects with
and without stone formation [27]. However, the bene-
ficial effect of taking calcium supplement with meal re-
sulted mainly from the reduction in urinary excretion of
oxalate, which was possibly secondary to a reduction in
gastrointestinal absorption, and an increase in urinary cit-
rate excretion. Both regimens of calcium supplement pro-
vided comparable urinary calcium excretions. Although
gastrointestinal calcium absorption may be enhanced in
some stone formers [27], resulting in less free calcium to
bind oxalate [28], the beneficial effect of calcium supple-
ment with meal still should be maintained. The higher
calcium absorption in some stone formers, in fact, would
strengthen the suggestion of taking calcium supplement
with meal.
Second, all the subjects in this study were male. The
extrapolation of our finding to female subjects should be
done with caution. However, the epidemiologic studies in
both women [6] and men [29] demonstrated that low cal-
cium intake was associated with higher incidence of cal-
cium stone formation. Our previous study on the effect
of calcium supplement in postmenopausal women also
demonstrated no significant change in the activity prod-
uct of calcium oxalate and a tendency to have lower uri-
nary oxalate excretion after taking calcium supplement
with meal [8]. Therefore, it is less likely for female sub-
jects to have different response to the two regimens of
calcium supplement.
CONCLUSION
Taking calcium supplement with a meal can avoid in-
creasing the risk of calcium stone formation without com-
promising intestinal calcium absorption. This is the result
of greater reduction in urinary oxalate and greater ele-
vation in urinary citrate excretion when taking calcium
supplement with meal. The effect of taking calcium with
meal still is maintained even in a population whose ox-
alate intake is rather low.
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